МОЛОДЁЖНЫЙ ПРОЕКТ ДЛЯ ТЕХ, КТО ДЕЛАЕТ ПЕРВЫЕ ШАГИ В НАУКЕ
 |  |
 |
/components/bitrix/system.auth.form/auth_alm/images/login.gif)
Войти /components/bitrix/system.auth.form/auth_alm/images/register.gif)
Регистрация
Войти в корпоративную почту как автор/член редколлегии/рецензент журнала
ARBOR VITAE: ДРЕВО ЖИЗНИ/ ARBOR VITAE: TREE OF LIFE / ARBOR VITAE: BAUM DES LEBEN Школа научного мастерства: Первый МГМУ имени И.М. Сеченова / School of Scientific Excellence: Sechenov First Moscow State Medical University / Die Schule der wissenschaftlichen Meisterschaft: die Erste Moskauer staatliche medizinische I.M. Setschenow-Universität
DOI 10.24411/2227-9490-2018-12071
Демура Т.А., Никанорова А.В.
Герминогенные гормон-продуцирующие опухоли яичников (обзор)
Демура Татьяна Александровна, доктор медицинских наук, профессор кафедры патологической анатомии им. академика А.И. Струкова ФГАОУ ВО «Первый МГМУ им. И.М. Сеченова» Минздрава России (Сеченовский университет)
ORCID ID https://orcid.org/0000-0002-6946-6146
E-mail: tatiana-a-demura@j-spacetime.com; demura-t@yandex.ru
Никанорова Александра Владимировна, студентка 5 курса лечебного факультета ФГАОУ ВО «Первый МГМУ им. И.М. Сеченова» Минздрава России (Сеченовский университет)
ORCID ID https://orcid.org/0000-0001-9188-9148
E-mail: alexandra-v-nikanorova@j-spacetime.com; nikanorovaalex@gmail.com
Герминогенные гормон-продуцирующие опухоли яичников встречаются относительно редко (2—3% от всех злокачественных опухолей яичника), но вопросы их ранней диагностики стоят наиболее актуально в связи с тем, что данные опухоли отличаются бессимптомным течением, выраженной степенью злокачественности, быстрым темпом роста, ранним распространением на близлежащие органы и метастазированием, в том числе в висцеральные органы. В 2013 г. была пересмотрена классификация ВОЗ герминогенных гормон-продуцирующих опухолей яичников. Используя современные материалы, был составлен литературный обзор, основанный не только на клиническом течении, но и на гистологической, молекулярной и иммуногистохимической диагностике, без которых невозможно достоверно поставить диагноз. Использование данных комплексных методов диагностики позволяет своевременно поставить диагноз, а также оценить прогноз заболевания и возможность безрецидивного течения.
Ключевые слова: герминогенные опухоли яичников; гормон-продуцирующие опухоли яичников; гормонально активные опухоли яичников; иммуногистохимические маркеры опухоли яичников; молекулярные маркеры опухоли яичников.
Цитирование по ГОСТ Р 7.0.11—2011:
Демура, Т. А., Никанорова, А. В. Герминогенные гормон-продуцирующие опухоли яичников (обзор) [Электронный ресурс] / Т.А. Демура, А.В. Никанорова // Электронное научное издание Альманах Пространство и Время. — 2018. — Т. 16. — Вып. 3—4. DOI: 10.24411/2227-9490-2018-12071. Стационарный сетевой адрес: 2227-9490e-aprovr_e-ast16-3_4.2018.071.
DOI: 10.24411/2227-9490-2018-12071
Demura T.A., Nikanorova A.V. Germinogenic Hormone-producing Ovarian Tumors (Review)
ORCID ID https://orcid.org/0000-0002-6946-6146
E-mail: tatiana-a-demura@j-spacetime.com; demura-t@yandex.ru
Alexandra V. Nikanorova, fifth year student at Sechenov First Moscow State Medical University
ORCID ID https://orcid.org/0000-0001-9188-9148
E-mail: alexandra-v-nikanorova@j-spacetime.com; nikanorovaalex@gmail.com
Germinogenic hormone-producing ovarian tumors are quite rare phenomenon (2–3% of all malignant tumors of the ovary), but their early diagnosis is acutely urgent problem since these tumors differ in an asymptomatic course, large degree of malignancy, rapid growth rate, early spread to nearby organs and metastasis, including metastatic spreading into visceral organs. Since in 2013, the WHO revised its classification of germ cell hormone-producing ovarian tumors, we found it useful to make a review of researches in this field, including both the most interesting works before 2013 and the most recent publications (like any scientific review, this one required the use of problem, source and comparative analysis, as well as the classification method).
We wrote review of recent scientific literature based not only on the clinical course, but also on histological, molecular and immunohistochemical diagnostic tips, which are important for reliable diagnostics.
Thus, we have examined in detail the studies of monodermal teratomas (ovarian goiter and carcinoid tumors), immature germ cell tumors (immature teratoma, dysgerminoma, choriocarcinoma, embryonic carcinoma) and malignant tumors of mixed germ cells, or polyembryoma. For each type of tumors, we isolated and represent descriptions of tumor growth relationship with patient's phenotype and, most crucially, molecular and immunohistochemical markers.
So, our review made it possible to attribute as key diagnostic methods not only morphological, but also immunohistochemical research. In cases of hormonally active ovarian tumors, scholars give a high status to molecular diagnostics. Thus, the BRAF mutation is crucial for ovarian goiter, staining for thyreoglobulin is positive in the cytoplasm of follicular cells, and for TTF-1 in the nuclei of tumor cells. Chromogranin and synaptophysin are the most useful immunohistochemical dyes for detecting carcinoid tumors. In a quarter of cases of dysherminomas, researchers detected c-KIT mutations, they describe CD117, D2-40 and placental alkaline phosphatase as the main dyes. Sources indicate that choriocarcinoma is positively stained for hCG, keratin, hPL and inhibin, embryonic carcinoma is positively stained for nuclear markers OCT-4, SALL-4 and SOX-2, as well as positive CK, PLAP and NSE, but negative for EMA.
This review allowed us to conclude that the minimal histochemical study is highly specific and sensitive, which makes it possible to use it as the method of choice for the diagnosis of hormone-producing ovarian tumors. The use of such complex approach provides for timely diagnosis, as well as assessment of the disease prognosis and possibility of disease-free survival.
Keywords: germinogenic ovarian tumors; hormone-producing ovarian tumors; hormonally active ovarian tumors; immunohistochemical tumors markers for ovarian cancer; molecular tumor markers for ovarian cancer.
Cite MLA 7:
Demura, T. A., and A. V. Nikanorova. "Germinogenic Hormone-producing Ovarian Tumors (Review)." Electronic Scientific Edition Almanac Space and Time 16.3—4 (2018). DOI: 10.24411/2227-9490-2018-12071. Web. <2227-9490e-aprovr_e-ast16-3_4.2018.071>. (In Russian).
Список литературы / References
×Литература
Кумар В., Аббас А.К., Фаусто Н., Астер Дж.К. Основы патологии заболеваний по Роббинсу и Котрану / Под ред. Е.А. Коган, Р.А. Серова, Е.А. Дубовой, К.А. Павлова. В 3 т. Т. 3, главы 21—29. М.: Логосфера, 2016.
Ожиганова И.Н. Морфология рака яичников в классификации ВОЗ 2013 года // Практическая онкология. 2014. Т. 15. № 4. С. 143—152.
Cheng L., Zhang S., Talerman A., Roth L.M. "Morphologic, Immunohistochemical, and Fluorescence in Situ Hybridization Study of Ovarian Embryonal Carcinoma with Comparison to Solid Variant of Yolk Sac Tumor and Immature Teratoma." Human Pathology 41.5 (2010): 716—723.
Cossu-Rocca P., Zhang S., Roth L.M., Eble J.N., Zheng W., Abdul Karim F.W., Michael H., Emerson R.E., Jones T.D., Hattab E.M., Cheng L. "Chromosome 12p Abnormalities in Dysgerminoma of the Ovary: A FISH Analysis." Modern Pathology 16.19 (2006): 1—5.
Crum C.P., Nucci M.R. Diagnostic Gynecologic and Obstetric Pathology. Eds. S.R. Granter, B.E. Howitt, M.M. Parast, T.K. Boyd, K.R. Lee, and W.A. Peters, III. Philadelphia: Elsevier, 2017.
Desouki M.M., Lioyd J., Xu H., Cao D., Barner R., Zhao C. "CDX2 May Be a Useful Marker to Distinguish Primary Ovarian Carcinoid from Gastrointestinal Metastatic Carcinoids to the Ovary." Human Pathology 44.11 (2013): 2536—2541.
Ferguson A.W., Katabuchi H., Ronnett B.M., Cho K.R. "Glial Implants in GliomatosisPeritonei Arise from Normal Tissue, not from the Associated Teratoma." The American Journal of Pathology 159.1 (2001): 51—55.
Fletcher C.D.M., ed. Diagnostic Histopathology of Tumors. Philadelphia: Elsevier, 2013, volumes 1. 2.
Gray Hazard F.K., Masand R. "Ovarian Dysgerminomas Pathology Overview of Ovarian Dysgerminomas." Medscape. N.p., 27 Oct. 2015. Web. <https://emedicine.medscape.com/article/1951026-overview#showall>.
Green A.E., Garcia A.A., Ahmed S. "Ovarian Cancer." Medscape. N.p., 12 Apr. 2018. Web. <https://emedicine.medscape.com/article/255771-overview#a3>.
Hara F., Samuel S., Liu J., Rosen D., Langley R.R., Naora H. "A Homeobox Gene Related to Drosophila Distal-LessPromotes Ovarian Tumorigenicity by Inducing Expression of Vascular Endothelial Growth Factor and Fibroblast Growth Factor-2." The American Journal of Pathology 170.5 (2007): 1594—1606.
McCluggage W.G. "Immunohistochemical Markers as a Diagnostic Aid in Ovarian Pathology." Diagnostic Histopathology 14.8 (2008): 335—351.
Oliva E., Young R.H. "Germ Cell Tumours of the Ovary: Selected Topics." Diagnostic Histopathology 20.9 (2014): 364—375.
Rubinsak L., Rivlin M.E. "Struma Ovarii." Medscape. N.p., 2 Mar. 2016. Web. <https://emedicine.medscape.com/article/256937-overview#showall>.
Schacht V., Dadras S.S., Johnson L.A., Jackson D.G., Hong Y.K., Detmar M. "Up-Regulation of the Lymphatic Marker Podoplanin, a Mucin-Type Transmembrane Glycoprotein, in Human Squamous Cell Carcinomas and Germ Cell Tumors." The American Journal of Pathology 166.3 (2005): 913—921.
Sever M., Jones T.D., Roth L.M., Abdul Karim F.W., Zheng W., Michael H., Hattab E.M., Emerson R.E., Baldridge L.A., Cheng L "Expression of CD117 (C-Kit) Receptor in Dysgerminoma of the Ovary: Diagnostic and Therapeutic Implications." Modern Pathology 22.18 (2005): 1—6.
Tebbi C.K., Windle M.L., Cripe T.P., Coppes M.J., Sakamoto K.M. "Carcinoid Tumor." Medscape. N.p., 16 Oct. 2017. Web. <https://emedicine.medscape.com/article/986050-overview#showall>.
Ulbright T.M. "Germ Cell Tumors of the Gonads: A Selective Review Emphasizing Problems in Differential Diagnosis, Newly Appreciated, and Controversial Issues." Modern Pathology 17.18 (2005): 1—19.
References:
Cheng L., Zhang S., Talerman A., Roth L.M. "Morphologic, Immunohistochemical, and Fluorescence in Situ Hybridization Study of Ovarian Embryonal Carcinoma with Comparison to Solid Variant of Yolk Sac Tumor and Immature Teratoma." Human Pathology 41.5 (2010): 716—723.
Cossu-Rocca P., Zhang S., Roth L.M., Eble J.N., Zheng W., Abdul Karim F.W., Michael H., Emerson R.E., Jones T.D., Hattab E.M., Cheng L. "Chromosome 12p Abnormalities in Dysgerminoma of the Ovary: A FISH Analysis." Modern Pathology 16.19 (2006): 1—5.
Crum C.P., Nucci M.R. Diagnostic Gynecologic and Obstetric Pathology. Eds. S.R. Granter, B.E. Howitt, M.M. Parast, T.K. Boyd, K.R. Lee, and W.A. Peters, III. Philadelphia: Elsevier, 2017.
Desouki M.M., Lioyd J., Xu H., Cao D., Barner R., Zhao C. "CDX2 May Be a Useful Marker to Distinguish Primary Ovarian Carcinoid from Gastrointestinal Metastatic Carcinoids to the Ovary." Human Pathology 44.11 (2013): 2536—2541.
Ferguson A.W., Katabuchi H., Ronnett B.M., Cho K.R. "Glial Implants in GliomatosisPeritonei Arise from Normal Tissue, not from the Associated Teratoma." The American Journal of Pathology 159.1 (2001): 51—55.
Fletcher C.D.M., ed. Diagnostic Histopathology of Tumors. Philadelphia: Elsevier, 2013, volumes 1. 2.
Gray Hazard F.K., Masand R. "Ovarian Dysgerminomas Pathology Overview of Ovarian Dysgerminomas." Medscape. N.p., 27 Oct. 2015. Web. <https://emedicine.medscape.com/article/1951026-overview#showall>.
Green A.E., Garcia A.A., Ahmed S. "Ovarian Cancer." Medscape. N.p., 12 Apr. 2018. Web. <https://emedicine.medscape.com/article/255771-overview#a3>.
Hara F., Samuel S., Liu J., Rosen D., Langley R.R., Naora H. "A Homeobox Gene Related to Drosophila Distal-LessPromotes Ovarian Tumorigenicity by Inducing Expression of Vascular Endothelial Growth Factor and Fibroblast Growth Factor-2." The American Journal of Pathology 170.5 (2007): 1594—1606.
Kumar V., Abbas A.K., Fausto N., Aster J.С. Robbins and Cotran Pathologic Basis of Disease. Moscow: Logosfera Publisher, 2016, volume 3. (In Russian).
McCluggage W.G. "Immunohistochemical Markers as a Diagnostic Aid in Ovarian Pathology." Diagnostic Histopathology 14.8 (2008): 335—351.
Oliva E., Young R.H. "Germ Cell Tumours of the Ovary: Selected Topics." Diagnostic Histopathology 20.9 (2014): 364—375.
Ozhiganova I.N. "Morphology of Ovarian Cancer in 2013 WHO Classification." Practical Oncology 15.4 (2014): 143—152. (In Russian).
Rubinsak L., Rivlin M.E. "Struma Ovarii." Medscape. N.p., 2 Mar. 2016. Web. <https://emedicine.medscape.com/article/256937-overview#showall>.
Schacht V., Dadras S.S., Johnson L.A., Jackson D.G., Hong Y.K., Detmar M. "Up-Regulation of the Lymphatic Marker Podoplanin, a Mucin-Type Transmembrane Glycoprotein, in Human Squamous Cell Carcinomas and Germ Cell Tumors." The American Journal of Pathology 166.3 (2005): 913—921.
Sever M., Jones T.D., Roth L.M., Abdul Karim F.W., Zheng W., Michael H., Hattab E.M., Emerson R.E., Baldridge L.A., Cheng L "Expression of CD117 (C-Kit) Receptor in Dysgerminoma of the Ovary: Diagnostic and Therapeutic Implications." Modern Pathology 22.18 (2005): 1—6.
Tebbi C.K., Windle M.L., Cripe T.P., Coppes M.J., Sakamoto K.M. "Carcinoid Tumor." Medscape. N.p., 16 Oct. 2017. Web. <https://emedicine.medscape.com/article/986050-overview#showall>.
Ulbright T.M. "Germ Cell Tumors of the Gonads: A Selective Review Emphasizing Problems in Differential Diagnosis, Newly Appreciated, and Controversial Issues." Modern Pathology 17.18 (2005): 1—19.
